Research programme: obesity therapy - Myriad Pharmaceuticals

Drug Profile

Research programme: obesity therapy - Myriad Pharmaceuticals

Alternative Names: MPI 176792; MPI 6802; obesity therapy research programme - Myriad Pharmaceuticals

Latest Information Update: 13 Aug 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Myriad Pharmaceuticals
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 13 Aug 2007 Discontinued - Preclinical for Obesity in USA (unspecified route)
  • 19 Apr 2006 No development reported - Preclinical for Obesity in USA (unspecified route)
  • 03 Oct 2005 Myriad announced the discovery of COB1, the first common gene to be associated with childhood obesity
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top